• 25 May 2018

    The public offer by Alexion Pharmaceuticals, Inc. through Alexion Pharma Nordics Holding AB (“Alexion”) for the shares in Wilson Therapeutics AB (publ) (“Wilson”) was declared unconditional today, 25 May 2018. Alexion owns more than 90 per cent of the shares in Wilson and intends to request compulsory acquisition in respect of the remaining shares in Wilson. The acceptance period for Alexion’s offer has been extended up to and including 8 June 2018, 3:00 p.m. CET, to allow remaining shareholders in Wilson to accept the offer.

  • 22 May 2018

    Immunocore Limited, a leading T cell receptor (TCR) company focused on delivering first-in-class biological therapies that have the potential to transform lives, today announces that new data from its phase I/II dose escalation trial of its wholly-owned, lead programme, IMCgp100, in metastatic uveal melanoma (mUM) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on 4 June 2018. 

  • 21 May 2018

    Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, is pleased to note that the Company was the winner of the 2018 Vale4Business (V4B) Award for Large Business of the Year.

  • 17 May 2018

    Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company and an innovator in the management of liver disease & malignant ascites, announces two important developments at the recent EASL (European Association for the Study of the Liver) International Liver Congress 2018. First, the inclusion of alfapump® in the EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis was announced, and secondly, the study by Macdonald et al reported that the physical component of health-related quality of life (“QoL”) is an independent predictor of mortality in refractory ascites patients.

  • 10 May 2018

    Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases, today reported business highlights and financial results for the first quarter ended March 31, 2018.